CUE

Cue Biopharma Inc

0.74

-0.01-1.79%

Closed16:00 08/01 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE0.7500/0.7506

TODAY RANGE0.7064-0.7899

VOL211.72K

MARKET CAP55.55M

52 WEEK RANGE0.4500-1.989

AVG VOL (3M)327.33K

% TURNOVER0.28%

TURNOVER--

P/E (TTM)-1.1096

% RANGE11.12%

EPS(TTM)-0.6644

P/E(FORWARD)-1.3404

P/B6.93

BVPS0.1064

DIVIDEND--

P/S4.908

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP55.35M

SHARES OUTSTANDING75.35M

NEXT EARNINGS08/12-08/18

FREE FLOAT75.08M

LOT SIZE1

EX-DATE--

News

Press Releases

Financial Reports

Profile

Benzinga·07/16 21:06
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga·07/16 17:06
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga·07/16 16:06
Reported Earlier: Cue Biopharma Reports 50% Overall Response Rate And 88% 12-Month Survival In CUE-101 Trial For HPV+ Cancers
TipRanks·07/16 12:06
Cue Biopharma provides clinical update on CUE-101, saw ORR of 50%
Reuters·07/16 12:00
CUE BIOPHARMA INC - 12-MONTH OVERALL SURVIVAL OF 88% AND MEDIAN SURVIVAL OF 32 MONTHS
Reuters·07/16 12:00
CUE BIOPHARMA REPORTS NEW COMPLETE RESPONSE AND CONFIRMED 50% OVERALL RESPONSE RATE IN ONGOING PHASE 1 TRIAL OF CUE-101 AND PEMBROLIZUMAB IN RECURRENT/METASTATIC HPV+ HEAD AND NECK CANCER
Benzinga·07/01 21:05
12 Health Care Stocks Moving In Tuesday's After-Market Session
TipRanks·07/01 20:43
Cue Biopharma Amends License Agreement with MIL 40G
TipRanks·07/01 20:20
Cue Biopharma announces presentation of new CUE-101 data
Benzinga·07/01 20:08
Cue Biopharma Issues Update On Its Clinical Stage Asset, CUE-101, Representative Of CUE-100 Series; Data Highlights Include ORR Of 50% In Treatment-Naive Patients With HPV+ R/M HNSCC
Reuters·07/01 20:05
CUE BIOPHARMA INC - 12-MONTH SURVIVAL OF 88% AND MOS OF 32 MONTHS
Reuters·07/01 20:05
CUE BIOPHARMA PROVIDES UPDATE ON MOST ADVANCED CLINICAL STAGE ASSET, CUE-101, PRESENTED BY DR. DIMITRIOS COLEVAS AT THE DAVA 4TH HAWAII GLOBAL SUMMIT ON THORACIC MALIGNANCIES
Dow Jones·06/24 21:16
Cue Biopharma Gets Positive FDA Feedback on Trial Design
TipRanks·06/24 20:55
Cue Biopharma receives Pre-IND feedback from FDA for CUE-401
Benzinga·06/24 20:50
Cue Biopharma Receives FDA Pre-IND Feedback For Lead Autoimmune Therapy CUE-401; Plans IND Filing Pending Final Studies

Same Industry

Name/Symbol

Change%

Price

Cue Biopharma Inc

CUE

-1.79%

0.7372

Regeneron Pharmaceuticals

REGN

+2.46%

558.87

Entero Therapeutics

ENTO

-4.45%

0.4204

BIONTECH

BNTX

-0.15%

107.34

United Therapeutics Corp.

UTHR

+7.13%

294.28

Siga Technologie

SIGA

-2.27%

6.46

Vertex Pharmaceuticals Inc

VRTX

+1.15%

462.13

Moderna

MRNA

-6.61%

27.61

Charles Riv Labs Intl Inc

CRL

-1.61%

166.91

Medpace Holdings

MEDP

-0.96%

423.09

Talphera Inc

TLPH

-3.73%

0.4024

ICON PLC

ICLR

-1.63%

166.44

China Biologic

CBPO

119.99

Iqvia Hldgs Inc

IQV

-1.83%

182.45

MOLECULAR PARTNERS AG

MOLN

-4.59%

3.53

PRA Health

PRAH

165.21

Arcturus Therape

ARCT

+0.74%

12.30

Gilead Sciences Inc

GILD

+0.79%

113.18

Aptevo Therapeutics Inc

APVO

-3.94%

2.68

Incyte Corp

INCY

+0.93%

75.59

Biospecifics

BSTC

+0.15%

88.53

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Contact Number : +852 3852 8500Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English